Apretude is a medicine approved by the FDA in 2021 to reduce the risk of contracting HIV through sexual contact, also known as pre-exposure prophylaxis (PrEP). PrEP is used to prevent the transmission ...

Apretude is a long-acting injectable medication used to prevent HIV (human immunodeficiency virus) infection in adults and some children who are at high risk of contracting the virus. Apretude is ...

Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds ...

The application is supported by data from the phase 2b/3 HPTN 083 and HPTN 084 trials, which evaluated the efficacy and safety of Apretude for HIV PrEP. The Food and Drug Administration (FDA) has ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...

Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...

(HealthDay)—The first injection drug to prevent HIV infection was approved by the U.S. Food and Drug Administration on Monday. "Today's approval adds an important tool in the effort to end the HIV ...

Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition Approved in the US for use in adults and ...

Nine out of ten HIV-negative adults in GSK's CLARITY study preferred Apretude over Gilead's Yeztugo, according to GSK. (iStock / Getty Images Plus) GSK’s ViiV Healthcare and its bimonthly pre-exposure ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...